PGEN
NASDAQ · Biotechnology
Precigen Inc
$4.22
-0.84 (-16.52%)
Financial Highlights (FY 2026)
Revenue
11.23M
Net Income
-291,130,840
Gross Margin
50.2%
Profit Margin
-2,588.2%
Rev Growth
-28.9%
D/E Ratio
4.46
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 50.2% | 50.2% | 42.3% | 42.3% |
| Operating Margin | -1,141.1% | -1,027.0% | -7.4% | -9.4% |
| Profit Margin | -2,588.2% | -2,458.8% | -8.5% | -8.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 11.23M | 15.79M | 411.38M | 421.12M |
| Gross Profit | 5.64M | 7.93M | 173.84M | 177.96M |
| Operating Income | -128,191,063 | -162,175,930 | -30,534,477 | -39,472,830 |
| Net Income | -291,130,840 | -368,312,842 | -34,816,902 | -35,997,358 |
| Gross Margin | 50.2% | 50.2% | 42.3% | 42.3% |
| Operating Margin | -1,141.1% | -1,027.0% | -7.4% | -9.4% |
| Profit Margin | -2,588.2% | -2,458.8% | -8.5% | -8.6% |
| Rev Growth | -28.9% | -28.9% | +17.8% | -9.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 626.49M | 626.49M | 657.59M | 697.63M |
| Total Equity | 140.60M | 140.60M | 694.85M | 748.63M |
| D/E Ratio | 4.46 | 4.46 | 0.95 | 0.93 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -124,661,295 | -166,472,069 | -49,679,638 | -48,292,540 |
| Free Cash Flow | — | — | -21,385,787 | -28,685,035 |